TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children ages 6 mo- 18 years~* Any ethnicity~* Diagnosed with atopic dermatitis (AD) per Hanifin-Rajka criteria~* Mild to moderate atopic dermatitis per Rajka-Langeland severity index~* Willing to use only provided cream and body wash for duration of study~Exclusion Criteria:~* Known sensitivity to investigational products~* Pregnant or breastfeeding~* Severe AD per Rajka-Langeland severity index~* AD requiring class I (super potent) or class II or III (potent) topical steroids~* Requires greater than 2.0 g inhaled or intranasal corticosteroids~* Other skin conditions which may interfere with the scoring of AD

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 19306-127 (Type: EXPERIMENTAL): Experimental Topical cream applied twice daily (or as needed)
- 19306-137 (Type: OTHER): Marketed Topical cream applied twice daily (or as needed)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erector Spinae Block vs Morphine in Vertebral Fixation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II-III~* written informed consent signed~* traumatic or degenerative disease~* adult age (18-65 year old)~Exclusion Criteria:~* allergies to local anesthetics~* contraindications to ESP block execution~* congenital or drug-induced coagulopathies~* infections at the puncture site~* BMI \> 40

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Erector spinae plane block + patient controlled analgesia (PCA) with intravenous morphine (Type: EXPERIMENTAL): Preoperative bilateral ESP block with ropivacaine 0,4% + dexamethasone 4 mg, 20 mL per side, at the median spinal level of intervention.~End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day.
- Patient controlled analgesia (PCA) with intravenous morphine (Type: ACTIVE_COMPARATOR): End-surgery: acetaminophen 1 g ev + 4 mg morphine ev before the end of the intervention.~PCA: morphine 1 mg, max every 30 minutes. Rescue: ketoprofen 100 mg ev, max three times per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* has type 2 diabetes mellitus~* is male, a female who cannot have children, or a female who agrees to use birth control during the study~* is not on an antihyperglycemic agent (AHA) (hemoglobin A1c \[A1C\] 7.5-11.0%) or on oral single AHA (A1C 7.0-10.5%) or low-dose AHA combination therapy (A1C 7.0-10.0%)~Exclusion Criteria:~* Patient has type 1 diabetes mellitus or ketoacidosis~* Patient is taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin)~* Patient is on a weight loss program not in the maintenance phase or on a weight loss medication~* Patient has a history of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer~* Patient is HIV positive~* Patient is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 50 mg + metformin 500 mg (Type: EXPERIMENTAL): Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
- Sitagliptin 50 mg + metformin 850 mg (Type: EXPERIMENTAL): Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
- Metformin 500 mg (Type: ACTIVE_COMPARATOR): Metformin 500 mg twice daily for 24 weeks.
- Metformin 850 mg (Type: ACTIVE_COMPARATOR): Metformin 850 mg twice daily for 24 weeks.
- Sitagliptin 100 mg (Type: EXPERIMENTAL): Sitagliptin 100 mg once daily for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methoxyflurane vs Standard Analgesic Treatment for Trauma Pain in Spanish Emergency Units

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients: ≥ 18 years of age~* Moderate to severe pain (NRS 0-10; \>=4) secondary to trauma~* Without anticipating surgery due to the trauma, requiring hospitalization (hospital stay 12h)~* Conscious patient.~* Giving informed consent in writing~Exclusion Criteria:~* Hypersensitivity to methoxyflurane (MEOF) or any fluorinated anaesthetic.~* Malignant hyperthermia: patients with known or genetically susceptible to malignant hyperthermia or a history of severe adverse reactions in either patient or relatives.~* Patients who have a history of showing signs of liver damage after previous MEOF use or halogenated hydrocarbon anaesthesia~* Known clinically significant renal impairment~* Known pregnant or likely to be pregnant women at the time of inclusion.~* Clinically evident cardiovascular instability~* Clinically evident respiratory depression~* Patients taken any analgesic for the traumatic pain before inclusion~* Altered level of consciousness due to any cause, including head injury, drugs or alcohol~* Degenerative diseases, mental illness or other conditions that could affect ability of valuing pain intensity~* Patients to be unable to understand the purpose of the study and perform self-assessments, following investigator's criteria.~* Participation in another clinical trial within 30 days prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methoxyflurane (Type: EXPERIMENTAL): Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
- Standard of Care (SoC) (Type: ACTIVE_COMPARATOR): Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells in Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females with non-child bearing potential in the age group of 18-60 yrs of Indian origin.~* Established CLI, clinically and hemodynamically confirmed as per Rutherford- II-4, III-5, or III-6; Patients having Infra-inguinal arterial occlusive disease with rest pain or ischemic ulcer/necrosis, who are not eligible for or have failed traditional revascularization treatment (No option patients)~* Ankle Brachial Pressure Index (ABPI) ≤ 0.6 or ankle pressure ≤ 70 mm Hg or TcPO2 ≤ 60 mmHg in the foot~* Patients if having associated Type II Diabetes, should be on medication and well controlled (HbA1c ≤ 8%) without complications~* Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits~* Normal liver and renal function~* On regular medication for hypertension if any~Exclusion Criteria:~* Patients with CLI suitable for surgical or percutaneous revascularization as determined by the surgeon performing vascular procedure and patients with any acute/chronic inflammatory condition~* CLI patient requiring amputation proximal to trans-metatarsal level~* Patients with gait disturbance for reasons other than CLI.~* Type I diabetes~* Patients having respiratory complications/left ventricular ejection fraction \< 25%f) Stroke or myocardial infarction within last 3 months~* Patients who are contraindicated for MRA~* Have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy~* Documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 1 year~* Patients already enrolled in another investigational drug trial or completed within 3 months.~* History of severe alcohol or drug abuse within 3 months of screening.~* Hb% \< 10 gm%, Serum Creatinine ≥ 2mg%, Serum Total Bilirubin ≥2mg%, HbA1c \> 8%~* Women with child bearing potential, pregnant and lactating women.~* Patients tested positive for HIV 1, HCV, HBV,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- mesenchymal stem cells (Type: EXPERIMENTAL): Intramuscular injection
- Placebo (Type: EXPERIMENTAL): Intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with locally advanced or metastatic nonsquamous non-small cell lung cancer~* Patients must be non-smokers~* Patients must have at least one measurable lesion~* Performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale~* Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease.~Exclusion Criteria:~* Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication~* Patients who have previously received treatment with drugs against the human epidermal growth factor receptors~* Patients who have previously received treatment with drugs which have similar targets as Pemetrexed~* Patients who have any known significant ophthalmologic abnormalities of the surface of the eye~* Patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Erlotinib (Type: EXPERIMENTAL): Pemetrexed 500 milligrams per meter squared (mg/m\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
- Erlotinib (Type: ACTIVE_COMPARATOR): Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
- Pemetrexed (Type: ACTIVE_COMPARATOR): Pemetrexed 500 mg/m\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of XP12B in Women With Menorrhagia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with menorrhagia~* 18-49 years of age~* Regularly occurring menstrual periods~Exclusion Criteria:~* History or presence of clinically significant disease or abnormalities that may confound the study~* History of bilateral oophorectomy or hysterectomy~* Hormone therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
There are two categories of participants: Patients with Burkitt Lymphoma, Diffuse large B-cell lymphoma or retinoblastoma; and health providers at BMC who participate in testing and/or use of mNavigator. Eligibility criteria are as follows:~A) For patients:~\*All patients will be registered in the pre-diagnosis cohort but, for the purposes of this study, primary and secondary outcomes will only be tracked for patients with BL, DLBCL or RB once the diagnosis is made.~Inclusion Criteria:~* Inclusion criteria are pediatric oncology patients diagnosed with Burkitt Lymphoma, Diffuse large B-cell lymphoma or Retinoblastoma under the age of 18~Exclusion criteria:~* Patients older than 18 years at registration~* Patients with diagnoses other than Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.~B) For providers:~Inclusion Criteria:~* Must be health provider or staff working at BMC who provides care for cancer patients.~* Must be 18 years of age or older.~Exclusion:~- Persons younger than 18 years of age.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mNavigator (Type: EXPERIMENTAL): Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
- Historical controls (Type: NO_INTERVENTION): BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Naltrexone on Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must give written informed consent~* Male or female subjects, \> 18 years~* Patients must have endoscopic, histologic, or radiographic confirmed Crohn's Disease.~* Patients must have a Crohn's Disease Activity Index (CDAI) of at least 220 at Baseline~* Stable doses of medications for Crohn's disease over proceeding 4 weeks (for aminosalicylates and steroids: prednisone of 10mg or less daily and Entocort 3 mg/ day are allowed), and 12 weeks for azathioprine or 6-mercaptopurine.)~Exclusion Criteria:~* Subjects with ostomies or ileorectal anastomosis from prior surgical colectomy.~* Subjects who received infliximab (Remicade) within 8 weeks of study screening or humira for 4 weeks.~* Subjects requiring steroids either intravenously or prednisone \>10mg /day or Entocort \> 3 mg daily.~* Subjects with short-bowel syndrome.~* Abnormal liver enzymes at screening visit or known hepatitis or cirrhosis~* Hemoglobin less than 10.~* Subjects with cancer (other than skin cancer) in past 5 years.~* Women of childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide), and willing and able to continue contraception for 3 months after the completion of the study.~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo, Sugar pill (Type: PLACEBO_COMPARATOR): placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
- Naltrexone-HCl (Type: ACTIVE_COMPARATOR): Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-Operative Inclusion Criteria~* Subject is scheduled for an elective cranial procedure involving a dural incision using any of the following surgical locations/approaches (or combination): frontal, temporal, occipital, and parietal (i.e. supratentorial), and/or midline or lateral suboccipital (i.e. infratentorial.) Subject requires a procedure involving a Class 1/clean wound (uninfected surgical wound in which no inflammation is encountered)~Intra-Operative Inclusion Criteria~* Subject's linear extent of durotomy is ≥2 cm~* Subject's dural margins from the edges of bony defect are ≥3 mm throughout~* Subject's CSF leak is present intra-operatively following completion of primary dural closure (with or without non-autologous duraplasty or autologous tissue), either spontaneously or upon Valsalva maneuver, at up to 20 cm H2O for up to five (5) seconds~Exclusion Criteria:~* Subject requires a procedure involving a translabyrinthine, transsphenoidal, transoral approach, or any procedure that penetrates the air sinus or mastoid air cells. Note: Superficial penetration of mastoid air cells is not an exclusion if cells are appropriately sealed (e.g. bone wax).~* Subject has a CSF shunt such as; ventriculo-peritoneal, ventriculo-pleural, ventriculo-atrial or lumbo-peritoneal shunts.~* Subject has an external ventricular or lumbar CSF drain that must be left in place after surgery.~* Subject has had radiation treatment to the surgical site, or standard fractionated radiation therapy is planned within ten days post index-procedure. (Note: stereotactic radiosurgery prior to the planned index procedure is not an exclusion criterion).~* Subject has a systemic infection or evidence of any infection near planned operative site.~Intra-Operative Exclusion Criteria~* Subject has an Incidental finding that meets any pre-operative exclusion criterion listed above.~* Subject requires the intra-operative placement of a CSF diversion device (e.g. ventricular catheter, subdural catheter, lumbar drain, or other device designed to externally evacuate CSF) that will be left in place after the procedure. Note: Subgaleal drains used for acute post-operative management of the incision site are permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DuraSeal Dural Sealant System (Type: ACTIVE_COMPARATOR): None
- Adherus Dural Sealant System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete